Lindbrook Capital’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Lindbrook Capital’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,050	Closed	-$4.58K	–	2901
2023 Q1	$4.58K	Hold	3,050	–	–	﹤0.01%	1888
2022 Q4	$3.05K	Hold	3,050	–	–	﹤0.01%	2046
2022 Q3	$5K	Hold	3,050	–	–	﹤0.01%	1712
2022 Q2	$9K	Hold	3,050	–	–	﹤0.01%	1326
2022 Q1	$8K	Hold	3,050	–	–	﹤0.01%	1418
2021 Q4	$14K	Buy	+3,050	New	+$19.1K	﹤0.01%	1155

Lindbrook Capital's TCRR Position: Q2 2023 in Review

Lindbrook Capital sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 3,050 shares — an estimated $4.58K sold.

Lindbrook Capital first reported a position in TCRR in Q4 2021 and held it in 6 quarters. The position peaked at $14K in Q4 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

Lindbrook Capital reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Lindbrook Capital sold 3,050 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $4.58K.
Lindbrook Capital first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Lindbrook Capital's TCR2 Therapeutics Inc. Common Stock position peaked at $14K in Q4 2021.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Lindbrook Capital's 13F filing for Q2 2023, filed 31 Jul 2023.